Treatment of chronic pelvic pain syndrome
The present invention provides compositions and methods for detection, diagnosis, treatment and/or prevention of chronic pelvic pain syndrome. In particular, the present invention provides biomarkers of chronic pelvic pain syndrome (e.g., mast cell markers (e.g., tryptase)), and/or inhibition of mast cell function (e.g. inhibition of MCP-1 and/or MIP-1α) to treat or prevent chronic pelvic pain syndrome.
1. A method for treating chronic pelvic pain syndrome in a subject, comprising administering to said subject a therapeutically effective amount of:
(a) a mast cell stabilizer;
(b) a combination of:
(i) a mast cell stabilizer and
(ii) a histamine receptor 1 antagonist and/or a histamine receptor 2 antagonist; or
(3) a combination of:
(i) a mast cell stabilizer,
(ii) a histamine receptor 1 antagonist and/or a histamine receptor 2 antagonist, and
(iii) an inhibitor of MCP-1 or MIP-1α, wherein the inhibitor is an antibody which binds MCP-1 or MIP-1α.
2. The method of claim 1 , wherein said subject is administered a mast cell stabilizer, but is not administered a histamine receptor 1 antagonist and/or histamine receptor 2 antagonist.
3. The method of claim 1 , wherein said subject is administered a combination of a mast cell stabilizer and a histamine receptor 1 antagonist and/or a histamine receptor 2 antagonist.
4. The method of claim 3 , wherein said subject is further administered an inhibitor of MCP-1 and/or MIP-1α, wherein the inhibitor is an antibody which binds MCP-1 or MIP-1α.
5. The method of claim 3 , wherein said histamine receptor 1 antagonist and/or histamine receptor 2 antagonist is a histamine receptor 1 antagonist.
6. The method of claim 5 , further comprising administering an inhibitor of MCP-1 or MIP-1α, wherein the inhibitor is an antibody which binds MCP-1 or MIP-1α.
7. The method of claim 3 , wherein said histamine receptor 1 antagonist and/or histamine receptor 2 antagonist is a histamine receptor 2 antagonist.
8. The method of claim 7 , further comprising administering an inhibitor of MCP-1 or MIP-1α, wherein the inhibitor is an antibody which binds MCP-1 or MIP-1α.
9. The method of claim 3 , wherein said subject is not administered an antibody which binds MCP-1 or MIP-1α.